Emerging evidence suggests that developmental T-ALL enhancers can be separated into thymocyte-active elements (e.g., Myc and Pten) and stem cell–active elements (e.g., Myb and Mycn) (34, 35, 90, 91). The gene discussed is MYCN; the disease is acute lymphoblastic leukemia.